{"doi":"10.1002/ijc.34689","title":"A prospective cohort study identifies two types of <scp>HIV</scp>+ Kaposi Sarcoma lesions: proliferative and inflammatory","abstract":"<jats:title>Abstract</jats:title><jats:p>Kaposi sarcoma (KS) is the most common cancer in people living with HIV (PLWH) in many countries where KS‐associated herpesvirus is endemic. Treatment has changed little in 20 years, but the disease presentation has. This prospective cohort study enrolled 122 human immunodeficiency virus (HIV) positive KS patients between 2017 and 2019 in Malawi. Participants were treated with bleomycin, vincristine and combination antiretroviral therapy, the local standard of care. One‐year overall survival was 61%, and progression‐free survival was 58%. The 48‐week complete response rate was 35%. RNAseq (n = 78) differentiated two types of KS lesions, those with marked endothelial characteristics and those enriched in inflammatory transcripts. This suggests that different KS lesions are in different disease states consistent with the known heterogeneous clinical response to treatment. In contrast to earlier cohorts, the plasma HIV viral load of KS patients in our study was highly variable. A total of 25% of participants had no detectable HIV; all had detectable KSHV viral load. Our study affirms that many KS cases today develop in PLWH with well‐controlled HIV infection and that different KS lesions have differing molecular compositions. Further studies are needed to develop predictive biomarkers for this disease.</jats:p>","journal":"International Journal of Cancer","year":2023,"id":633835,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":597416,"name":"Edwards Kasonkanji","orcid":"0000-0002-1543-814X","position":1,"is_corresponding":false},{"id":601282,"name":"Joe Gumulira","orcid":null,"position":2,"is_corresponding":false},{"id":814435,"name":"Yolanda Gondwe","orcid":"0000-0002-1225-9461","position":3,"is_corresponding":false},{"id":334761,"name":"Morgan Dewey","orcid":"0009-0003-2236-9415","position":4,"is_corresponding":false},{"id":776314,"name":"Yue Pan","orcid":"0000-0003-1958-2744","position":5,"is_corresponding":false},{"id":1048823,"name":"Alice Peng","orcid":"0000-0003-1877-2001","position":6,"is_corresponding":false},{"id":1577387,"name":"Linda J. Pluta","orcid":null,"position":7,"is_corresponding":false},{"id":964425,"name":"Evaristar Kudowa","orcid":null,"position":8,"is_corresponding":false},{"id":598045,"name":"Richard Nyasosela","orcid":null,"position":9,"is_corresponding":false},{"id":597426,"name":"Tamiwe Tomoka","orcid":"0000-0002-5183-8714","position":10,"is_corresponding":false},{"id":597212,"name":"Hannock Tweya","orcid":"0000-0002-8247-1273","position":11,"is_corresponding":false},{"id":598750,"name":"Tom Heller","orcid":"0009-0008-4626-0592","position":12,"is_corresponding":false},{"id":598751,"name":"Salem Gugsa","orcid":"0000-0003-3545-3117","position":13,"is_corresponding":false},{"id":361250,"name":"Sam Phiri","orcid":"0000-0002-9372-212X","position":14,"is_corresponding":false},{"id":589930,"name":"Dominic T. Moore","orcid":null,"position":15,"is_corresponding":false},{"id":263811,"name":"Blossom Damania","orcid":"0000-0002-9205-1774","position":16,"is_corresponding":false},{"id":281457,"name":"Matthew Painschab","orcid":"0000-0001-9175-7436","position":17,"is_corresponding":false},{"id":312050,"name":"Mina C. Hosseinipour","orcid":"0000-0003-2174-313X","position":18,"is_corresponding":false},{"id":295812,"name":"Dirk P. Dittmer","orcid":"0000-0003-4968-5656","position":19,"is_corresponding":false},{"id":334450,"name":"Razia Moorad","orcid":"0000-0001-5688-5766","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A prospective cohort study identifies two types of <scp>HIV</scp>+ Kaposi Sarcoma lesions: proliferative and inflammatory","abstract":"<jats:title>Abstract</jats:title><jats:p>Kaposi sarcoma (KS) is the most common cancer in people living with HIV (PLWH) in many countries where KS‐associated herpesvirus is endemic. Treatment has changed little in 20 years, but the disease presentation has. This prospective cohort study enrolled 122 human immunodeficiency virus (HIV) positive KS patients between 2017 and 2019 in Malawi. Participants were treated with bleomycin, vincristine and combination antiretroviral therapy, the local standard of care. One‐year overall survival was 61%, and progression‐free survival was 58%. The 48‐week complete response rate was 35%. RNAseq (n = 78) differentiated two types of KS lesions, those with marked endothelial characteristics and those enriched in inflammatory transcripts. This suggests that different KS lesions are in different disease states consistent with the known heterogeneous clinical response to treatment. In contrast to earlier cohorts, the plasma HIV viral load of KS patients in our study was highly variable. A total of 25% of participants had no detectable HIV; all had detectable KSHV viral load. Our study affirms that many KS cases today develop in PLWH with well‐controlled HIV infection and that different KS lesions have differing molecular compositions. Further studies are needed to develop predictive biomarkers for this disease.</jats:p>","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37602960","pmcid":"PMC11074775","openalex_id":"https://openalex.org/W4386019407","authors":[],"funders":[{"funder_name":"U.S. Public Health Service","grant_id":"CA019014","title":null},{"funder_name":"U.S. Public Health Service","grant_id":"CA121947","title":null},{"funder_name":"U.S. Public Health Service","grant_id":"CA23958","title":null},{"funder_name":"U.S. Public Health Service","grant_id":"CA254564","title":null},{"funder_name":"U.S. Public Health Service","grant_id":"DE018304","title":null},{"funder_name":"FIC NIH HHS","grant_id":"K01 TW011470","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P01 CA019014","title":null},{"funder_name":"NIDCR NIH HHS","grant_id":"R01 DE018304","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA121947","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U54 CA254564","title":null},{"funder_name":"NCI NIH HHS","grant_id":"D43 CA260641","title":null}],"total_grants":11,"fwci":1.6166,"citation_percentile":0.85332457,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":7},{"year":2025,"count":6}],"oa_status":"green","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11074775/pdf/nihms-1984593.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11074775/pdf/nihms-1984593.pdf","host_type":"repository"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34689","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11074775","host_type":"repository"},{"url":"https://doi.org/10.1002/ijc.34689","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37602960","host_type":"repository"}],"fields_of_study":["Viral-associated cancers and disorders","Lymphoma Diagnosis and Treatment","Histiocytic Disorders and Treatments"],"mesh_terms":["HIV","Humans","Prospective Studies","Sarcoma, Kaposi","HIV Infections","Herpesvirus 8, Human"],"keywords":["Medicine","Sarcoma","Prospective cohort study","Viral load","Cohort","Cancer","Bleomycin","Internal medicine","Kaposi's sarcoma","Disease","Immunology","Vincristine","Oncology","Human immunodeficiency virus (HIV)","Chemotherapy","Pathology","Cyclophosphamide","Human herpesvirus","Differential gene expression","clinical study","Kaposi Sarcoma Herpesvirus","Transcriptome Rna Sequencing"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:45:55.580416Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}